Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Voyager Therapeutics, Inc. (VYGR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.07-0.41 (-6.33%)
At close: 04:00PM EDT
6.37 +0.30 (+4.94%)
After hours: 07:36PM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • B
    Berk
    This will go parabolic soon!
    Bullish
  • J
    Johny
    Edging up to $10 again
  • P
    Papa
    anyone know if VYGR's approach same as recent pair of high-profile disappointments have been reported, including one just announced on a trial of the Eli Lilly drug solanezumab. VYGR doing something different?
  • J
    Jeremy
    Anyone know what's going on here?
    down 16% today
  • R
    Redposition
    Holding well in red market !
  • a
    art
    If you fully read today's release, it states "at the the ASGCT for one capsid candidate demonstrating more than 1,000-fold increased transgene expression compared to conventional AAV9" This is huge people. This means much smaller dosing for patients which means much less risk. This is what the FDA is looking for from Biotech companies.

    Today's Pfizer deal validates that this Novel Capsid is the real deal. And I am guessing we will see many bigger collaborations with big biotech in the next year. Don't listen to the shorts, they have no deep analysis in this, other than their little gifs and memes. The stock has been quiet and beaten down over the past year, and now the cat is out of the bag. And the shorts got stuck with their hands in the cookie jar.

    Also look at the financials, $160+ million Voyager has in cash vs. a market cap of approximately $135 million / $3.90/share? This is a no brainer undervalued stock for both the short and long term investor.

    Jump on board before the next set of good news comes out and this snowballs!
    Bullish
  • J
    Julian
    Voyager Therapeutics plunges after update on board composition
    Apr. 21, 2022 3:55 PM ETVoyager Therapeutics, Inc. (VYGR)By: Dulan Lokuwithana, SA News Editor
    BOARD; Wooden blocks with "BOARD" text of concept and human toys.
    Seiya Tabuchi/iStock via Getty Images

    The shares of gene therapy company, Voyager Therapeutics (NASDAQ:VYGR) have recorded the biggest intraday loss on Thursday after announcing that two of its board members had requested not to be nominated for re-election at the upcoming annual shareholder meeting.
    Directors of the board, Mark Levin and Steven Paul made the request on April 14 in consultation with the Nominating and Corporate Governance Committee, the company said in a regulatory filing.
    The duo cited the need to cut work commitments and the number of board of other public firms they serve as reasons for their decision.
    They “confirmed that such request was not based upon any disagreement with the Board or with the management on any matter relating to the Company’s operations, policies or practices,” Voyager (VYGR) added. The company has obtained the services of a search firm to find the replacements.
  • J
    John
    Important features from Q3 results :

    1. Loss less than expected -0.67 compared to -0.75 expected
    2. Cash position to remain same as last year at end of 2021
    3. No dilution
  • M
    Mo
    10K AT $3 and still not selling. The day any of their tracer platforms reaches the clinical phase, this stock will be worth over hundreds dollars. Here is why VYGR is different from any other biotech, small float, large amounts of cash on hand and low cash burn rate so very small chance of dilution and they already have major licensing deals worth billions of dollars with major pharmaceutical companies.
  • A
    AAA
    Current Market cap $200 mil. This should be at least 1 bil company based on rev, income, cash position and Pfizer deal. 5 fold from here. $28 per shares like a couple years ago.
    Bullish
  • J
    Jorge
    heavy drops at low volume. Institutions and long term holders loaded up already. MMs trying to buy cheap from FOMO paper hands that bought on the good news. I posted before the pop up this share is way undervalued and 1 good new away of exploding.We need to wait for a few months to see who are the institutions that loaded up. This company is a gem: good financials, great disrupting products, and lots of good news ahead. TBH I can't call for a sell price but I would not sell below 15$.
    Bullish
  • A
    Anonymous
    Great things happening. Green pastures ahead investors. I was very happy with the quarter and the faith of some behemoth companies in VYGR. Easy hold after today. They may play games with the share price in the short term to shake some confidence, but too bullish to stay down here for any sustained time.
  • B
    Boni
    “The licensing transaction with Pfizer showcases TRACER’s ability to produce not only enhanced blood-brain barrier penetrant capsids, but also novel capsids with enhanced tropism for cardiac muscle, offering promise to unlock the fullest potential of gene therapies for a wide array of diseases. We’ve retained all rights to our capsid library outside of their use with two particular Pfizer transgenes, and we believe there is significant opportunity for similar transactions leveraging the entirety of our libraries for other targets inside and outside of the CNS.”
    Bullish
  • M
    Mo
    This stock is worth $30 alone on financials right now and worth triple digits if human trials are successful. Don't let this little run up make you think you missed the boat.
  • d
    dusin
    This isnt a short squeeze play. This is running because they just turned profitable the year before. Huge money on Pfizer deal. No need to do offering in short term. was sitting at a low even though the company was moving the other direction. Buy and hold for a couple months. we will be in new highs soon enough.
  • A
    Anil
    Gene therapy is the future
    Signing a deal with Novartis “1.8 B” it’s huge and Pfizer deal inked last year. Gene 🧬 therapy is huge. Very positive
  • H
    Heemball
    $BIGG.CN conversation
    If anyone wants a comparison take a look at #VYGR on December 9th. And a few days before. Virtually identical to BIGG today....except VYGR is at $19 CAD. Just a little profit taking today and maybe tomorrow and then $4 by the end of March, $8 by April 15th....
  • B
    Boni
    Excellent close for the week. Longs should be happy as this still has a long way to go upward based on fundamentals and no hype. Enjoy the weekend.
    Bullish
  • M
    M.sir
    135m market cap
    140m cash and current assets
    30m cash from Pfizer
    option for another potential $600m from Pfizer

    This should be trading double what it currently is...what gives?
  • S
    SONG
    I had stocks before Translate Bio was acquired by Sanofi.
    A day before the takeover offer, Translate Bio crashed for no reason, and there were people spreading rumors of clinical failureAnd the next morning, Sanofi announced an acquisition offer.
    I feel like the movement today is similar to that time
    Bullish
Advertisement
Advertisement